



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

ATTY.'S DOCKET: KINOSHITA=

In re Application of:) Art Unit: 1617
Shigeru KINOSHITA) Examiner: S.M.R. HUI
Serial No.: 09/623,138) Confirmation No. 9673
Filed: August 28, 2000) Washington D.C.
For: LANGERHANS CELL MIGRATION) May 16, 2002
INHIBITORS)

TECH CENTER 1600/2909

MAY 20 2002

RECEIVED

SUPPLEMENTAL AMENDMENT

Honorable Commissioner for Patents
Washington, D.C. 20231

Supplemental to the amendment filed

March 25, 2002, please enter the following Supplemental
Amendment:

IN THE CLAIMS

Please amend claim 11 as follows:

11. (Twice Amended) A method for inhibitory
ocular Langerhans cell migration in a mammal comprising
administering an effective amount of a Langerhans cell
migration inhibitor comprising a compound selected from
calcitriol; $1\alpha,24$ -dihydroxy vitamin D_3 ; α -calcidol;
calcifedol; $1\alpha,25,26$ -trihydroxy vitamin D_3 ; $1\beta,25$ -
dihydroxy vitamin D_3 ; 24 -homo- $1\alpha,25$ -dihydroxy vitamin D_3 ;
 26 -homo- $1\alpha,25$ -dihydroxy vitamin D_3 ; 22 -oxacalcitol; and
calcipotriol as an active ingredient to the mammal.

Sub E1
D1

In re Application of: Shigeru KINOSHITA
 Serial No.: 09/623,138
 Filed: August 28, 2000
 For: LANGERHANS CELLS MIGRATION INHIBITORS

Art Unit: 1617
 Confirmation No.: 9673
 Examiner: S.M.R. HUI
 Washington, D.C.
 Atty.'s Docket: KINOSHITA-3
 Date: May 16, 2002

THE COMMISSIONER OF PATENTS AND TRADEMARKS
 Washington, D.C. 20231

Sir:

Transmitted herewith is an ☐ Amendment ☒ Supplemental Amendment
 in the above-identified application.

- ☐ Small entity status of this application under 37 CFR 1.9 and 1.27 has been established by a verified statement previously submitted.
☐ A verified statement to establish small entity status under 37 CFR 1.9 and 1.27 is enclosed.
☒ No additional fee is required.

The fee has been calculated as shown below:

	(Col. 1)		(Col. 2)		(Col. 3)		Small Entity		Other Than a Small Entity
	Claims Remaining After Amendment		Highest No. Previously Paid For		Present Extra		Rate	Additional Fee	
Total	6	Minus	20		0		x 9	\$	x18
Indep.	1	Minus	3		0		x42	\$	x84
First Presentation of Multiple Dependent Claim							140	\$	+280
TOTAL ADDITIONAL CLAIMS FEE								\$	Total

* If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.

** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, write "20" in this space.

*** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, write "3" in this space.

1. The "Highest Number Previously Paid For" (total or independent) is the highest number found from the equivalent box in Col.1 of a prior amendment of the number of claims originally filed.

☒ Conditional Petition for Extension of Time

If any extension of time for a response is required applicant requests that this be considered a petition therefor.

☐ It is hereby petitioned for an extension of time in accordance with 37 CFR 1.136(a). The appropriate fee required by 37 CFR 1.17 is calculated as shown below:

Small Entity

Response Filed Within

- ☐ First - \$ 55.00
☐ Second - \$200.00
☐ Third - \$460.00
☐ Fourth - \$720.00

Other Than Small Entity

Response Filed Within

- ☐ First - \$ 110.00
☐ Second - \$ 400.00
☐ Third - \$ 920.00
☐ Fourth - \$1440.00

☐ Less fees (\$) already paid for months extension of time on

☐ Please charge my Deposit Account No. 02-4035 in the amount of \$. A duplicate copy of this sheet is attached.

☐ A check in the amount of \$ is attached (check no.).

☐ Credit Card Payment Form, PTO-2038, authorizing payment in the amount of \$ is attached.

☒ The Commissioner is hereby authorized and requested to charge any additional fees which may be required in connection with this application or credit any overpayment to Deposit Account No. 02-4035. This authorization and request is not limited to payment of all fees associated with this communication, including any Extension of time fee, not covered by check or specific authorization, but is also intended to include all fees for the presentation of extra claims under 37 CFR Section 1.16 and all patent processing fees under 37 CFR Section 1.17 throughout the prosecution of the case. This blanket authorization does not include patent issue fees under 37 CFR Section 1.18.

BROWDY AND NEIMARK
 Attorneys for Applicant(s)

Facsimile: (202) 737-3528
 Telephone: (202) 628-5197

By:

Anne M. Kornbau
 Registration No. 25,884

AMK:nmp

G:\BN\Y\YUAS\KINOSHITA3\pto\cov2.wpd